Your SlideShare is downloading. ×
PowerPoint Presentation
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

PowerPoint Presentation


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide
  • Add the company between the green lines. You can just type their name if they don’t have a website. Open by
  • Transcript

    • 1. Bringing your projects to a higher level.
    • 2. Agenda
      • Introductions of Cato Team
      • Company Profile
      • Today’s Presentation
    • 3. Cato Research Team
      • Andrée Lefebvre, B.Sc. RAC
      • Director, Regulatory Affairs &
      • Assistant Managing Director
      • Cato Research Canada
      • Christine Warrington
      • Global Strategic Sales and Marketing
      • Headquarter Office Durham, NC
    • 4. Company Profile We are a full-service contract research and development organization with global resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the drug development process in order to bring new drugs, biologics, and medical devices to the people who need them.
    • 5. Cato Research
      • Full service financially stable global drug development company headquartered in RTP, NC. Global presence.
      • Founded in 1988 -20 year anniversary
      • Over 300 Employees
      • Project teams lead by Ph.Ds and MDs
      • Established Cato Research Drug Fellowship Program
      • Clients include pharmaceutical, biotechnology, venture capital and academia
    • 6. Therapeutic Expertise
      • Oncology
      • Neurology/Psychiatry
      • Cardiology
      • Gastroenterology
      • Dermatology
      • Endocrinology/Metabolic Disorders
      • Infectious Disease
      • Immunology
      • Hematology
      • Ophthalmology
      • Nephrology
      • Pulmonology
      • Rheumatology
      • Vascular Disorders
      • Anesthesiology and Pain
      • Rare Diseases
    • 7. Cologne, Germany Frankfurt, Germany Riga, Latvia Graz, Austria Szeger, Hungary Zagreb, Croatia Tel-Aviv, Israel Johannesburg, South Africa San Diego, CA San Francisco, CA Montreal, Canada Boston, MA Washington, MD Durham, NC Worldwide Locations Collaborations Poland Romania Russia Ukraine India
    • 8. Full Service Development Services
      • Clinical Trial Services - Phases 1 to 4
      • Pharmacovigilance
      • Medical Monitoring
      • Data Management
      • Biostatistics
      • Regulatory
      • Quality Assurance
      • Chemistry, Manufacturing, and Controls (CMC)
      • Nonclinical
      • Strategic Consulting
    • 9. Quality Assurance Best Practices in a Good Laboratory Practice Environment
    • 10. First, a few words from the wise…
      • The basic concepts underlying quality systems are quite simple:
      • Say what you do,
      • do what you say,
      • prove it and
      • improve it
      • Janet Woodcook, M.D.
      • Director, Center for Drug Evaluation and Research
      • FDA
    • 11. Why do we need GLP?
      • In the 1950's, 1960's and 1970's, Industrial Bio-Test Laboratories (IBT) performed about 35-40% of all U.S. toxicology testing
      • Of 867 audits of IBT performed by the FDA under the 1962 law, 618 studies were invalid due to numerous discrepancies between the study conduct and data
      • FDA sued and the courts found four IBT managers guilty of fraud
      • As a result of the IBT incident, the FDA decided to regulate laboratory testing
      • In 1976, the FDA GLP guidelines were proposed; they were finalized in 1978 and became effective in 1979
    • 12. Good Laboratory Practice for Nonclinical Laboratory Studies Title 21 Code of Federal Regulations Part 58
      • The goal is to demonstrate SAFETY of test article before use in humans
      • Do controlled, well-documented laboratory studies
      • Use prospective and approved protocols
      • Document testing methods and findings
      • Provide Quality Assurance review
    • 13. Organization of GLPs
      • GLP Subpart B ––
      • GLP Subpart C ––
      • GLP Subpart D ––
      • GLP Subpart E ––
      • GLP Subpart F ––
      • ARTICLES
      • GLP Subpart G ––
      • GLP Subparts H-I ––
      • [RESERVED]
      • GLP Subpart J ––
      • GLP Subpart K ––
    • 14. The 10 Commandments of GLP
      • Thou shalt appoint study directors and quality assurance
      • Thou shalt be competent, as a result of education, training and experience
      • Honor thy protocol and thy SOPs
      • Thou shalt conduct studies in adequate and clean facilities
      • Thou shalt identify test and control articles and document their use
    • 15. The 10 Commandments of GLP
      • 6 . Thou shalt maintain and calibrate equipment according to a specified schedule
      • 7. Thou shalt document and correct all deviations
      • 8. Thou shalt not commit fraud; all thy work thou shalt note, sign and date
      • 9. Thou shalt have archives
      • 10.Thou shalt not turn your back on the FDA
    • 16. A Few Definitions
      • Nonclinical laboratory study
        • in vivo or in vitro experiments in which test articles are studied prospectively in test systems under laboratory conditions to determine their safety
        • NOT studies utilizing human subjects, clinical studies, field trials in animals, basic exploratory studies for utility, for determining physical or chemical characteristics of a test article
    • 17. A Few Definitions (cont.)
      • 4 important parts of a GLP study
      • Sponsor
      • Management
      • Study Director (SD)
      • Quality Assurance Unit (QAU)
    • 18. A Few Definitions (cont.)
      • Sponsor
        • A person who initiates and supports a study with financial or other resources
        • A person who submits a nonclinical study to FDA
        • A testing facility, if it both initiates and actually conducts the study
    • 19. A Few Definitions (cont.)
      • Management
        • Designates a study director before the study starts
        • Replaces the study director promptly if necessary during the study
        • Assures that there is a quality assurance unit
        • Assures that test and control articles or mixtures are tested for identity, strength, purity, stability, and uniformity
    • 20. A Few Definitions (cont.)
      • Management (continued)
        • Assures that personnel, resources, facilities, equipment, materials, and methodologies are available as scheduled
        • Assures that personnel clearly understand the functions they are to perform
        • Assures that any deviations from these regulations reported by the quality assurance unit are:
          • communicated to the study director
          • and corrective actions are taken and documented
    • 21. A Few Definitions (cont.)
      • Study Director
        • Scientist of appropriate education, training and experience
        • Responsible for overall technical conduct of a nonclinical laboratory study and for the interpretation, analysis, documentation and reporting of results
        • Assures that all study records are archived at the end of the study
    • 22. A Few Definitions (cont.)
      • Quality Assurance Unit
        • any person or organizational element, designated by management to perform the duties relating to QA of nonclinical laboratory studies
    • 23. §58.15 Inspection of a testing facility
      • A testing facility SHALL permit FDA to inspect the facility and to inspect (and copy) all records and specimens
      • Except
        • quality assurance unit records of findings, or corrective actions recommended and taken
      • FDA will not consider a study for a marketing permit if the testing facility refuses to permit inspection and the applicant still must submit the results of the study to FDA!
    • 24. §58.35 Quality Assurance Unit
      • Duties
        • QAU monitors each study to assure management that all systems are in conformance with GLP regulations
        • QAU shall be entirely independent of personnel conducting a particular study
    • 25. §58.35 Quality Assurance Unit (cont.)
      • Duties
        • The quality assurance unit shall:
          • Maintain a master schedule sheet of all studies, indexed by test article and listing these elements:
            • test system, nature of study, study initiation date, current status, sponsor identity, and name of the study director
    • 26. §58.35 Quality Assurance Unit (cont.)
      • Duties
        • Maintain copies of all GLP protocols
        • Inspect each nonclinical laboratory study at adequate intervals; maintain written signed records of periodic inspections
        • Bring to the attention of the study director and management immediately any problems found during an inspection that may affect study integrity
    • 27. §58.35 Quality Assurance Unit (cont.)
      • Duties
        • Periodically submit to management and to the study director written status reports on each study, noting problems and corrective actions taken
        • Determine that no deviations from approved protocols or standard operating procedures were made without authorization and documentation
    • 28. §58.35 Quality Assurance Unit (cont.)
      • Duties
        • Review the final study report to assure accuracy in description of methods and Standard Operating Procedures, and that results accurately reflect the raw data of the study
        • Prepare and sign a statement specifying dates of inspections and when findings were reported to management and study director
    • 29. The QAU SOPs (and related)
      • Topics:
        • GLP Training
        • QA training within the GLP environment
        • Structure of the QAU, e.g.
          • Inspection group, archiving group, validation group
        • QA Reporting Systems, e.g.
          • To respond to QA findings
          • To report to management (including trend analysis)
    • 30. The QAU SOPs (and related)
      • Topics (continued):
        • Good documentation practices
        • “Inspection” of computer systems
        • QA Master Schedule
        • Archiving procedures (including off site archiving)
          • Disaster recovery plan
        • Data Audit
    • 31. Good Documentation Practice
      • Documentation should permit the complete reconstruction of a study
        • Record data directly, promptly and legibly in indelible ink (never pencil)
        • Initial and date all observations and any resulting changes, but do not obscure original data
        • Initial and date only work you’ve performed
        • Do not document selectively or in advance of performing the activity
    • 32. Good Documentation Practice
      • Do not use white-out correction fluid or tape
      • Do not use ditto marks as raw data
      • Copy all heat sensitive paper and stamp “exact copy”
      • Explain why any raw data not used was not used
      • Verify critical calculations using a second person and document this
      • Notebook pages requiring a second signature shall be completed with that signature
    • 33. Good Documentation Practice
      • Properly head all pages, tables, columns; identify units
      • Describe Statistical & Calculation Procedures used
      • Sign, Date, and File automated printouts (e.g., QC forms)
      • Retain all Raw Data (original records) in the Study File
      • Do not document by exception. Use positive documentation, even if only a check mark.
    • 34. Good Documentation Practice
      • Documentation must allow another person to be able to accurately reconstruct what you have done
      • Keep all original observations including those observations recorded directly into a computer
      • Sign and date all computer printouts
      • Never back-date anything
      • Follow SOPs and Protocol
    • 35. Good Documentation Practice
      • Document all deviations with accompanying explanations
      • Indicate in the record all applicable units and equipment used
    • 36. Raw Data Correction
      • All changes to raw data must be made without obscuring the original entry
      • All changes must be initialed and dated by the person making the change, accompanied by an explanation for the change
    • 37. Abbreviations for Reasons Ignore single line cross-off Original Entry OK STET Ignore single line cross-off Original Entry OK OE-OK Entry is illegible or has been overwritten Not Legible NL Number shown is the result of a miscalculation Miscalculation MC Data are already correctly entered elsewhere Repeated Data RD Entered word is misspelled Spelling Error SP Entry of a wrong number or incorrect word Erroneous Entry EE Definition Meaning Notation
    • 38. Now, you have selected a CRO…
    • 39. The due diligence starts…
    • 40. Reference: Compliance Program Guidance for FDA Staff
      • BIMO – Bioresearch Monitoring
        • 7348.808 Good Laboratory Practice (Nonclinical Laboratories) – FDA version
        • 7348.808A Good Laboratory Practice Program (Nonclinical Laboratories) – EPA Data Audit Inspection
    • 41. Bottom Line…
      • 7348.808 Good Laboratory Practice (Nonclinical Laboratories) is FDA’s instruction manual for its inspectors’ use when they “audit” your GLP facility or study(ies)
      • Be pro-active, and make sure you know what they’ll want to see
    • 42. INSPECTIONAL General Instructions
      • Determine the current state of GLP compliance by evaluating the laboratory facilities, operations, and study performance
      • Organization Chart - If the facility maintains an organization chart, obtain a current version of the chart for use during your inspection
    • 43. INSPECTIONAL General Instructions (cont.)
      • Facility Floor-plan –
        • Obtain a diagram of the facility
        • Identify any areas that are not used for GLP activities
        • Use the floor plan during the inspection to ensure that it is really up-to-date
    • 44. INSPECTIONAL General Instructions (cont.)
      • Master Schedule Sheet
        • Obtain a copy of the firm's master schedule sheet
        • Determine who decides if a study is a GLP study
      • FDA 483’s
        • Obtain a copy and review findings
    • 45. Areas of Expertise of the Facility
      • Testing facilities may conduct one or more types of GLP studies.
        • Physical-chemical testing
        • Toxicity studies
        • Mutagenicity studies
        • Tissue residue depletion studies
        • Analytical and clinical chemistry testing
        • Other studies (specify)
    • 46. SOP Evaluation
      • Review the SOP index and representative samples of SOPs to ensure coverage of all of the areas identified in GLPs
      • Verify that only current SOPs are available at the personnel workstations
      • Review key SOPs in detail and check for proper authorization signatures and dates, and general adequacy with respect to the content (i.e., SOPs are clear, complete, and can be followed by a trained individual)
    • 47. SOP Evaluation (cont.)
      • Verify that changes to SOPs are properly authorized and dated and that a historical file of SOPs is maintained
      • Ensure that there are procedures for familiarizing employees with SOPs
      • Determine that there are SOPs to ensure the quality and integrity of data, including input (data checking and verification), output (data control), and an audit trail covering all data changes
    • 48. SOP Evaluation (cont.)
      • Verify that a historical file of outdated or modified computer programs is maintained. If the firm does not maintain old programs in digital form, ensure that a hard copy of all programs has been made and stored.
      • Verify that SOPs are periodically reviewed for current applicability and that they are representative of the actual procedures in use
      • Review selected SOPs and observe employees performing the operation to evaluate SOP adherence and familiarity
    • 49. If the firm has computerized operations, determine…
      • Who was involved in the design, development, and validation of the computer system?
      • Who is responsible for the operation of the computer system, including inputs, processing, and output of data?
      • Determine whether computer system personnel have training commensurate with their responsibilities, including professional training and training in GLPs.
    • 50. If the firm has computerized operations, also determine…
      • Whether some computer system personnel are contractors who are present on-site full-time, or nearly full-time
        • Include these contractors as though they were employees of the firm
        • Specific inquiry may be needed to identify these contractors, as they may not appear on organization charts
      • Interview and observe personnel using the computerized systems to assess their training and performance of assigned duties
    • 51. Equipment Computers
      • For computer systems, assess that the following procedures exist and are documented:
        • Validation study, including validation plan and documentation of the plan's completion
        • Maintenance of equipment, including storage capacity and back-up procedures
      • Control measures over changes made to the computer system, which include the evaluation of the change, necessary test design, test data, and final acceptance of the change
    • 52. Equipment Computers (cont.)
      • Evaluation of test data to assure accurate transmission and proper handling when analytical equipment is directly interfaced to the computer
      • Procedures for emergency back-up (e.g., battery system and data forms for recording data in case of computer failure or power outage)
    • 53. Storage and Retrieval of Records
      • Determine how and where computer data and backup copies are stored, that records are indexed in a way to allow access to data stored on electronic media, and that environmental conditions minimize deterioration
    • 54. Storage of Computer Records
      • Determine to what electronic media such as tape cassettes or ultra high capacity portable discs the test facility has the capacity of copying records in electronic form
      • Report names and identifying numbers of both copying equipment type and electronic medium type to enable agency personnel to bring electronic media to future inspections for collecting exhibits
    • 55. Assess the procedures by which the study director:
      • Is assigned and replaced
      • Assures the protocol and any amendments have been properly approved and are followed
      • Assures that all data are accurately recorded and verified
      • Assures that data are collected according to the protocol and SOPs
    • 56. Assess the procedures by which the study director also:
      • Documents unforeseen circumstances that may affect the quality and integrity of the study and implements corrective action
      • Assures that study personnel are familiar with and adhere to the study protocol and SOPs
      • Assures that study data are transferred to the archives at the close of the study
    • 57. QAU Operations
      • Ratio QA employees to all employees (5 to 8%)
      • Review and verify QAU SOPs to assure that they cover all methods and procedures for carrying out the required QAU functions, and confirm that they are being followed:
        • Maintenance of a master schedule sheet
        • Maintenance of copies of all protocols and amendments
        • Scheduling of its in-process inspections and audits
    • 58. QAU Operations (cont.)
      • Inspection of each nonclinical laboratory study at intervals adequate to assure the integrity of the study, and maintenance of records of each inspection
      • Immediately notify the SD and management of problems likely to affect the INTEGRITY of the study
      • Submission of periodic status reports on each study to the SD and management
    • 59. QAU Operations (cont.)
      • Review of the final study report
      • Preparation of a statement to be included in the final report that specifies the dates inspections were made and findings reported to management and to the SD
      • Inspection of computer operations
      • Training
    • 60. More scrutiny of QAU
      • Verify that, for any given study, the QAU is entirely separate from and independent of the personnel engaged in the conduct and direction of that study
      • Evaluate the time QAU personnel spend in performing in-process inspection and final report audits
        • Determine if the time spent is sufficient to detect problems in critical study phases and if there are adequate personnel to perform the required functions
    • 61. Facilities
      • Document any conditions that would lead to contamination of test articles or to unusual stress of test systems
      • Determine that computerized operations and archived computer data are housed under appropriate environmental conditions (e.g., protected from heat, water, and electromagnetic forces)
    • 62. Equipment (other than computers)
      • For representative pieces of equipment check the availability of the following:
        • SOPs and/or operating manuals
        • Maintenance schedule and log
        • Standardization/calibration procedure, schedule, and log
        • Standards used for calibration and standardization
    • 63. Testing Facilities Operations
      • Determine if the testing facility has established and follows written SOPs necessary to carry out study operations in a manner designed to ensure the quality and integrity of the data (including method validation)
      • Determine if the testing facility has appropriate controlled storage for study samples
      • Determine if the testing facility maintains and calibrates instrumentation as per SOPs
    • 64. Animal Care
      • Purpose: To assess whether animal care and housing are adequate to minimize stress and uncontrolled influences that could alter the response of test system to the test article
      • Inspect typical animal room(s) that will be housing your study
    • 65. Animal Care (cont.)
      • Review pest-control procedures and documentation of the chemicals used. Identify individuals responsible for the program. When a contractor provides the pest control, determine if someone from the laboratory accompanies the exterminator at all times.
      • Determine whether the facility has an Institutional Animal Care and Use Committee (IACUC). Obtain and submit a copy of the Committee's SOPs and most recent committee minutes to verify committee operation.
    • 66. Test and Control Articles
      • Characterization and Stability of Test Articles - The responsibility for carrying out appropriate characterization and stability testing may be assumed by the facility performing the study or by your company
      • If you intend to perform the test article characterization and stability testing, verify that the test facility has the procedure in place to document that this testing will have been conducted according to GLP (or GMP)
    • 67. Archiving
      • Determine the number of archive locations – waterproof? Fireproof?
      • Determine who is the individual assigned as archivist
      • Verify method of indexing and the time period when documents/slides/computer data are archived after completion of the study
    • 68. Your audit report
      • Classify your findings
        • Critical, major, minor or observations
      • Provide a compliance assessment statement
      • Summarize your audit and request a response within 30 days
    • 69. Remembering an FDA Inspection…
    • 70. A Big…
      • Thank you